anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Adverse events reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during the double-blind, placebo-controlled trials, regardless of causality, are listed in Table 1 below. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.

Urticaria was seen in 1.1% vs. 0%, and rash in 1.4% vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials. 

###  Increases in Liver Enzymes

In a pooled analysis of 10 placebo-controlled trials, increases to > 3 times the upper limit of normal in ALT occurred in 5.3% of patients taking fenofibrate at doses equivalent to 96 mg to 145 mg fenofibrate tablets daily versus 1.1% of patients treated with placebo [see Error! Hyperlink reference not valid.]. In an 8-week study, the incidence of ALT or AST elevations ≥ 3 times the upper limit of normal was 13% in patients receiving dosages equivalent to 96 mg to 145 mg fenofibrate tablets daily and was 0% in those receiving dosages equivalent to 48 mg or less fenofibrate tablets daily or placebo.
The invention discloses a preparation method of fusion antibacterial peptide for resisting main pathogenic bacteria of cow mastitis. By evaluating the bacteriostatic activity of the synthesized antibacterial peptides, two antibacterial peptides 'RGLRRLGRKIAHGVKKYGPTVLR IIRIAG' and 'LKRWKRVFKLLKRYWRQLKKKPVR' with the best antibacterial effect are screened, and are connected through a Flexible Linker 'GGGGS' to obtain the fusion antibacterial peptide. Constructing a specific expression vector, expressing the fused antibacterial peptide AP-14829 by using pichia pastoris X33, and evaluating the activity. The obtained fusion antibacterial peptide AP-14829 has stronger inhibition effect on several main pathogenic bacteria of cow mastitis, and the antibacterial effect is obviously better than that of a single antibacterial peptide. In vitro hemolytic experiments have confirmed that AP-14829 has no significant injurious effect on erythrocytes. Compared with prokaryotic expression, the polypeptide obtained by yeast expression is closer to a natural state, so that the activity is higher, and the normal running of the function of the polypeptide is ensured.
An exfoliating scrub cream, comprising a sugar alcohol as a scrubbing agent, a polyol as a base agent and a tackifier. The sugar alcohol is at least one selected from erythritol and xylitol. The polyol is a polyol which is liquid at 25 °C. On the basis of the total amount of the exfoliating scrub cream, the content of the sugar alcohol is 15-70 wt%. The tackifier is a tackifier comprising a structural unit as represented by the following formula (1) in the molecule, wherein, X is OH, ONa, OK, OR1 or R2, R1 can be an alkyl group, an amine group or a substituted amine group having 1-30 carbon atoms, and R2 can be an amine group, a substituted amine group, a sodium dimethyltaurate group, a potassium dimethyltaurate group or an ammonium dimethyltaurate group. The exfoliating scrub cream is substantially free of water. The exfoliating scrub cream has an excellent feeling of use when being used, and has stable product performance, being not liable to have reduced appearance or performance even if stored for a long period of time.
Topiramate, USP is a sulfamate-substituted monosaccharide. Topiramate capsules (sprinkle) are available as 15 mg and 25 mg sprinkle capsules for oral administration as whole capsules or opened and sprinkled onto soft food.

Topiramate, USP is a white crystalline powder with a bitter taste. Topiramate, USP is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate, USP is designated chemically as 2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate and has the following structural formula:

C12H21NO8S M.W. 339.36

Topiramate capsules (sprinkle) contain topiramate coated beads in a hard gelatin capsule. The inactive ingredients are: black iron oxide, ethylcellulose, gelatin, povidone, polyethylene glycol, propylene glycol, shellac, sugar spheres (which contain sucrose and corn starch), talc, titanium dioxide, and triethyl citrate.
An evening primrose oil facial cleanser is disclosed. Raw materials in a formula of the facial cleanser comprise, by weight, 15 parts of evening primrose oil, 40 parts of tallow, 1 part of octadecanol, 1 part of oleyl alcohol, 1 part of lanolin, 0.3 part of essence, a proper amount of a preservative, a proper amount of vitamin E, 6.5 parts of potassium hydroxide, 2 parts of sodium hydroxide and 34 parts of refined water. By dosage and physicochemical properties of the raw materials, synergism is produced so as to achieve the effects of deeply cleaning and improving skin microcirculation. The pH value of the facial cleanser is close to the pH value of human skin, and the facial cleanser is nonirritating to skin. After the use of the facial cleanser, skin is obviously comfortable and soft and has no oily feel. The facial cleanser has obvious effects of cleaning, moistening and protecting and beautifying skin.
Pediatric liver cancers are rare, affecting at times no more than 1 in one million population. Understanding the molecular basis of these cancers is important in order to develop more accurate diagnoses and more effective treatments. Current classifications of these cancers are based on how these cancers look on diagnostic studies such as radiologic imaging or under the microscope. Such a classification system does not explain why a particular cancer has a different outcome from what is considered "usual" for that particular cancer. Nor does such a classification system explain why two different classes of cancers behave the same way. Understanding the genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

To achieve these goals, large numbers of such cancer patients or affected tissue must be collected. This is not possible in any single institution, or any single country. The current project will collect biological samples such as residual tumor tissue, saliva, or blood from affected patients and their biological parents and families, along with clinical information about the cancer. These biological samples will be used to study the genes and how these genes work in tumor tissue and in non-tumor tissue. The results of this study will permit childhood liver cancers to be categorized on the basis of common defects in genes and their function.
The present invention relates to an apparatus for alarming a cosmetic harmful ingredient and for recommending cosmetics. The apparatus for alarming a cosmetic harmful ingredient and for recommending cosmetics comprises: a user input unit which outputs signals corresponding to selecting motions of a user; and a motion control unit. The motion control unit is connected to the user input unit, and when a request for recommending a cosmetic is received from the user input unit, uses signals input by the user input unit to determine a kind of cosmetics selected by the user. The motion control unit uses storage data of an ingredient database for each product to determine ingredients of each product corresponding to the determined kind of cosmetic, and determines a list of harmful ingredients classified as final harmful ingredients corresponding to the user in a final harmful ingredient database for each user. Then, the motion control unit compares mutually the determined ingredients and gives an arrangement order of products corresponding to the kind in a sequence of less containing of the final harmful ingredients among ingredients of each product, and outputs the corresponding products according to the arrangement order granted to products. The technical objective of the present invention is to improve user satisfaction by notifying harmful ingredients contained in products selected by a user. Moreover, the objective of the present invention is to facilitate user selection by recommending cosmetics fitted to the user.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention proposes agent as liquid or soft medicinal form containing cytokin taken at effective amount has additionally glycerol at amount 10-90 wt.-%. Claimed agent can contain recombinant interferon at amount 10 3 -10 7  IU/1 g of agent and/or recombinant tumor necrosis α-factor at amount 10 3 -10 7  IU/1 g of agent as cytokin. Claimed agent can contain additionally immunoglobulins at amount 1-60 wt.-%, among them as the mixture of IgA, IgG and IgM. EFFECT: increased preservation of cytokin activity in drug, enhanced effectiveness of its curative effect. 4 cl
Participants randomized to the Treatment Arm will received 1.0 plasma exchanges daily until discontinuation of vasopressors, death or to a maximum of 5 daily treatments. Solvent detergent plasma (SDP) or frozen plasma (FP) depending on availability will be used as the replacement fluid.
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorption of sodium and glucose. While many clinical trials demonstrated the tremendous potential of SGLT2i for cardiovascular diseases. 2022 AHA/ACC/HFSA guideline first emphasized that SGLT2i were the only drug class that can cover the entire management of heart failure (HF) from prevention to treatment. Subsequently, the antiarrhythmic properties of SGLT2i have also attracted attention. Although there are currently no prospective studies specifically on the anti-arrhythmic effects of SGLT2i. We provide clues from clinical and fundamental researches to identify its antiarrhythmic effects, reviewing the evidences and mechanism for the SGLT2i antiarrhythmic effects and establishing a novel paradigm involving intracellular sodium, metabolism and autophagy to investigate the potential mechanisms of SGLT2i in mitigating arrhythmias.
Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant's name, contact info, and organ needed into the Donor App's secure management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link the participant will be allowed to use the Donor App indefinitely.
The inclusions will be stratified to the deep neural network (DNN) score. The study will enrol 20 patients in each group.
The present invention relates to new crystals A, B and F of lobaplatin as well as preparation methods therefor and pharmaceutical applications thereof. Lobaplatin crystal A has a melting point Tm.p. of 220±5° C. and is obtained by adding a lobaplatin trihydrate to a suspension crystallization solvent. Lobaplatin crystal B has a melting point T m.p.  of 230±5° C. and is obtained by performing solvent evaporation on a lobaplatin trihydrate or by adding a solvent to a lobaplatin dihydrate, and performing room temperature evaporation or solventing-out crystallization and then drying. Lobaplatin crystal F has a melting point Tm.p. of 229±5° C. and is obtained by adding methanol or ethanol to a lobaplatin dihydrate, stirring at room temperature until solids are dissolved, filtering out insolubles, slowly adding an organic solvent, crystallizing out, separating the crystal and drying the crystal. Compared with the existing lobaplatin and lobaplatin trihydrate, the lobaplatin crystals A, B and F have better stability and solubility, are more suitable for preparation of various forms of pharmaceutical preparations, are more suitable for storage and use, and can be better used for treating cancers such as breast cancer, small cell lung cancer, or chronic myeloid leukemia.
Fibromyalgia (FM) is a chronic and widespread pain condition, usually accompanied by several associated symptoms such as fatigue, sleep disorder, headache, irritable bowel syndrome and mood disorders. Recent studies point to the possibility of gluten protein having a role in the development of FM symptoms in a subgroup of patients. Fourteen patients with FM diagnosis will be kept on a diet restrict in gluten-free foods for a period 10 weeks. At the 7th week they received rice protein isolate capsules (placebo) for 7 days, followed by a 3-day wash-out and a new challenge with capsules containing 8 g/day of gluten (corresponding to 6,3g gluten protein) for another 7 days. In the initial period, at 8th week (final of placebo period) and after challenge with gluten (10th week), blood will be collected for analysis of inflammatory markers. Questionnaires will be carried out to evaluate the quantity and severity of FM symptoms and the impact of FM on daily routine. Inflammatory markers (IL-1bera, IL-6 and IL-10) will be evaluated in the blood. In the challenger period (gluten or placebo) questionnaires will be carried out to evaluate the quantity and severity of symptoms related to fibromyalgia and the impact of fibromyalgia on a daily basis. In addition, a questionnaire based on Salerno protocol was applied to evaluate the presence of NCGS.
Biallelic CNTNAP2 variants have been associated with Pitt-Hopkins-like syndrome. We describe six novel and one previously reported patients from six independent families and review the literature including 64 patients carrying biallelic CNTNAP2 variants. Initial reports highlighted intractable focal seizures and the failure of epilepsy surgery in children, but subsequent reports did not expand on this aspect. In all our patients (n = 7), brain MRI showed bilateral temporal gray/white matter blurring with white matter high signal intensity, more obvious on the T2-FLAIR sequences, consistent with bilateral temporal lobe dysplasia. All patients had focal seizures with temporal lobe onset and semiology, which were recorded on EEG in five, showing bilateral independent temporal onset in four. Epilepsy was responsive to anti-seizure medications in two patients (2/7, 28.5%), and pharmaco-resistant in five (5/7, 71.5%). Splice-site variants identified in five patients (5/7, 71.5%) were the most common mutational finding. Our observation expands the phenotypic and genetic spectrum of biallelic CNTNAP2 alterations focusing on the neuroimaging features and provides evidence for an elective bilateral anatomoelectroclinical involvement of the temporal lobes in the associated epilepsy, with relevant implications on clinical management.
NEW MATERIAL:The peptide of formula or its salt. USE:Therapeutic and preventive agent for thrombosis. It has blood platelet coagu lation inhibiting action. PREPARATION:alpha-Casein is hydrolyzed with preferably 0.02-0.03 pts.wt. (based on 1 pt.wt. of casein) of pepsin in hydrochloric acid (preferably 0.1N acid). The hydrolyzed liquid is added with an alkali (preferably ammonia water) to adjust the pH of the reaction liquid to 4 and insoluble materials are removed to obtain an aqueous solution of the hydrolyzate. The solution is subjected to column chromatography packed with a cartin exchange material. The objec tive compound is separated from the resultant basic peptide mixture by treating the mixture with a high performance liquid chromatography using a column packed with an octadecylsilylated silica gel.
OBJECTIVE: The aim of the study is to evaluate how gait kinematics and muscle activity during robot-assisted gait training are affected by different combinations of parameter settings and a number of instruction types, ranging from no instructions to goal-specific instructions.
DESIGN: Robots for gait therapy provide a haptic guidance, but too much guidance can limit the active participation. Therapists can stimulate this active participation either with instructions or by adapting device parameters. How these two factors interact is still unknown. In the present study, we test the interaction of three different parameter settings and four instruction types in a cross-sectional study with 20 children and adolescents without impairment. Gait kinematics and surface electromyography were measured to evaluate the immediate effects.
RESULTS: We found that only goal-specific instructions in combination with a low guidance led to a moderate but significant change in gait kinematics. The muscle activity was altered by all instructions, but the biggest effect was found for goal-specific instructions with a 2.5 times higher surface electromyography amplitude compared to no instruction.
CONCLUSIONS: Goal-specific instructions are a key element of robot-assisted gait therapy interventions and device parameter adjustments may be used to modulate their effects. Therapists should pay close attention to how they instruct patients.
A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream of a shell solution, and an inner nozzle operable to discharge an inner stream of a core solution intermixed with a plurality of materials. The outer stream can substantially surrounds the inner stream, thereby forming a combined stream. A plurality of capsules can be formed responsive to a force applied to the combined stream. At least a portion of the plurality of capsules are desirable capsules, each having a core encapsulated by a portion of the shell solution. The core can have at least one of the plurality of materials encapsulated by a portion of the core solution without protruding an outer surface of the portion of the shell solution. Additional embodiments are disclosed.
Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
Studies of iron and erythroid cells, have provided fundamental insights into structure function relationships of proteins, energy metabolism, and the molecular basis of many diseases. Based upon the importance of iron for hemoglobin production, the regulation of erythropoiesis and iron metabolism are closely linked, and iron deficiency anemia remains as one of the most common diseases worldwide. The discovery of sickle hemoglobin as having an abnormal electrophoretic mobility marked the beginning of the molecular medicine era. The advent of recombinant DNA technology and sequencing methodologies resulted in the characterization of erythroid cells well beyond that of protein based studies to include gene structure and expression. Globin gene research, in particular, has provided a wealth of information about the expression, regulation and insulation of mammalian genes. More recently, studies of iron absorption and trafficking provided new avenues of research aimed toward growth and energy homeostasis. Genome based approaches were also utilized for the discovery of direct relationships between erythroid cell biology and iron homeostasis. Hence, there is strong evidence that fundamental clinical advances in the field of iron and erythroid biology have been based upon the careful study of humans with informative phenotypes. Clinically based correlation of genotype and phenotype is a proven, systematic approach for understanding the molecular basis of disease.

With the completion of the sequencing of the human genome, a more complete, genetically based description of disease is now achievable. Efforts aimed toward haplotype mapping will further enhance genotype phenotype correlation directly from clinical samples. Considerable progress has already been made in this regard using normal human erythroid cells. In contrast to classic studies involving single genes or proteins, computational biology and high throughput technologies permit the analysis of complex erythroid phenotypes including those with related iron pathologies. This information will be invaluable for understanding those molecular mechanisms that are altered in disease states.

The immediate aim of this protocol is to perform phenotypic analyses in humans with informative iron or erythroid phenotypes. These studies are expected to result in detailed clinical phenotyping and the collection and banking of clinical specimens for further study. In addition, we predict an ongoing growth of new technologies that may eventually be used for molecular and genetic phenotyping of clinical samples (examples include oligonucleotide chips and high throughput mass spectroscopy). Based upon this prediction, we plan to use the samples collected here to assess possible clinical uses of those technologies as they become available. The eventual aim is the discovery of identifiers that may be predictive of disease pathogenesis, severity or clinical response to intervention.
BACKGROUND: The rise of periprosthetic joint infections (PJIs) due to aging populations is steadily increasing the number of arthroplasties and treatment costs. This study analyzed the direct health care costs of PJI for total hip arthroplasty and total knee arthroplasty (TKA) in Europe.
METHODS: The databases PubMed, Scopus, Embase, Cochrane, and Google Scholar were systematically screened for direct costs of PJI in Europe. Publications that defined the joint site and the procedure performed were further analyzed. Mean direct health care costs were calculated for debridement, antibiotics, and implant retention (DAIR), one-stage, and 2-stage revisions for hip and knee PJI, respectively. Costs were adjusted for inflation rates and reported in US-Dollar (USD).
RESULTS: Of 1,374 eligible publications, 12 manuscripts were included in the final analysis after an abstract and full-text review. Mean direct costs of $32,933 were identified for all types of revision procedures for knee PJI. The mean direct treatment cost including DAIR for TKA after PJI was $19,476. For 2-stage revisions of TKA, the mean total cost was $37,980. For all types of hip PJI procedures, mean direct hospital costs were $28,904. For hip DAIR, one-stage and 2-stage treatment average costs of $7,120, $44,594, and $42,166 were identified, respectively.
CONCLUSIONS: Periprosthetic joint infections are associated with substantial direct health care costs. As detailed reports on the cost of PJI are scarce and of limited quality, more detailed financial data on the cost of PJI treatment are urgently required.